Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Captainblkon Mar 03, 2020 1:04pm

108 Views

Post# 30761595

RE:Speculation Time!

Scotty wrote: If KLY did get bought out, what price do you guys think would be reasonable? I'm going to lowball at 10-15c but would like to be wrong lol.

ive been trying to reason this out for months. that would put its market cap (roughly) around $50-100 million. that is excessively low IMHO if we are talking a buyout. personally I would think there would be 3 commas if a buyout were to take place

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?